SCHEMBL12596283

SCHEMBL12596283

Cc1nncn1Cc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.61
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
CYP11B1 P15538 4/20 0.44
CYP11B2 P19099 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 2/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 2/20 0.43
P2RX7 Q99572 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
GALR3 O60755 1/20 0.41
NR2F2 P24468 1/20 0.41
RAB9A P51151 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14476635 0.84 KCNH2 (0.46) KCNH2KDM4ECYP11B1CYP11B2P2RX7
SCHEMBL20413799 0.81 QPCTL (0.52) KCNH2KDM4EMAPTCYP11B1CYP11B2
SCHEMBL14204154 0.78 CYP11B1 (0.44) KCNH2POLBKDM4EMAPTCYP11B1
SCHEMBL17502249 0.77 KCNH2 (1.00) KCNH2KDM4EMAPTP2RX7
SCHEMBL14476844 0.76 P2RX7 (0.54) KCNH2KDM4EP2RX7CYP1A2CYP2C19
SCHEMBL12596382 0.72 POLB (0.61) KCNH2POLBKDM4EMAPTCYP11B1
SCHEMBL2950629 0.70 LMNA (0.71) KCNH2POLBSMN1; SMN2KMT2AMEN1
SCHEMBL14204156 0.69 TP53 (0.46) POLBMAPTCYP11B1CYP11B2SMN1; SMN2
SCHEMBL5983769 0.69 KCNH2 (0.43) KCNH2POLBKDM4EMAPTCYP11B1
SCHEMBL11380884 0.69 LMNA (0.47) POLBKDM4ECYP11B1CYP11B2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
WO-2009106817-A2 COMPOUND STERIX LIMITED (GB) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 KCNH2 3259/4885POLB 1401/4885KDM4E 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.